The results of MRI signal change demonstrated that the existence of targeting ligands greatly enhanced the T2 MRI signal of the tumor site 1 week after administration (Figure 4A).[140] In addition, some other nanoplatforms loaded with SPIONs and modified with a variety of targeting ligands (e.g., folic acid,[46, 47, 51, 118, 141, 142, 143, 144] lactoferrin,[145] peptide,[40, 57, 58, 59, 62, 146, 147] antibody[148, 149]) have also been developed to facilitate the accumulation into tumor tissues and provide the contrast enhancement in T2 MRI. The gene discussed is LTF; the disease is neoplasm.